Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  SpineGuard    ALSGD   FR0011464452

SPINEGUARD

(ALSGD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

16 September 2020 – 10h45 CET : SpineGuard morning note by BioStrategic Research (in english) (Télécharger le PDF)

share with twitter share with LinkedIn share with facebook
09/16/2020 | 09:45am EDT

Morning Note - 16th September 2020

SPINEGUARD

France - Medtech

H1: costs under control in the midst of the Covid storm

BUY

Sales logically impacted by the Covid crisis

Fair value (EUR)

0.85

A limited loss thanks to a good cost control

Price (EUR)

0.172

H2 should see a rebound in activity

Upside/down side

+ 394%

Many surgeries canceled during the March-May period

SpineGuard had published its H1 sales figures on july 9th which stood at EUR2.28m, a sharped decline of -34%(-50% for T2 alone). Unsurprisingly, the business was severely impacted by the health crisis which forced the postponement of most spine surgeries in order to free up capacity for Covid patients in the intensive care units of public and private hospitals. China did not generate any sales, with local partners having stocks built up before the lockdown period. For the first 6 months, the group publishes a stable gross margin rate (84.1% vs. 84.6% in H1 2019).

Operational loss under control

The lockdown period imposed a partial activity of the various services. The drop in sales has a direct impact on the variable part of the remuneration of agents in particular. The team limited its travel, promotional operations were fewer leading to an overall reduction in sales costs of around 30%. Administrative functions were less strained and also saw their costs decrease by around -15%. While teleworking made a "documentary" activity possible, the R&D activity was also impacted, notably with the temporary closure of the robotics laboratories at the Sorbonne, resulting in a decrease in R&D spending of around 35%.

The fall in sales was unavoidable, but good cost control limits the current operating loss to -EUR0.56m (vs. - EUR0.41m). The safeguard procedure did however induce non-recurring costs close to EUR0.6m. Management has negotiated with its lenders (Norgine, FEI) to delay the hearing (Commercial Court) to Q4 in return for payment of accrued interest. The financial burden therefore still weighs on the accounts and the net loss comes to -EUR1.39m (vs. -EUR0.81 m).

A gradual return to a "normal" situation

Unlike certain sectors which have experienced temporary reductions in activity that are little or very difficult to recover (leisure, transport, catering / hotels, for example), the deformities of the spine of almost all suffering patients did not disappear during the lockdown period. Spine surgeries have therefore been rescheduled and the need for medical devices (implants and ancillaries) remains intact. Sales should therefore gradually resume, conditioned nevertheless by the capacity of operating theaters and the impact of the disinfection protocols applied to prevent the risk of contamination by Covid-19 (limit the number of operations in a day). There is also uncertainty about the observed rebound in the spread of the virus which has already required mobility restrictions or even total containment decisions as very recently in Israel.

Lionel Labourdette, PhD, MBA

lionel@biostrategic-research.com+33 617 965 019

Stock data (2020-09-15)

ISIN

FR0011464452

Ticker

ALSGD.PA

Price (EUR)

0.172

Market capitalisation (EURm)

3.6

Free float (%) est.

85,0

Floating capitalisation (EURm)

3.1

Number of shares (,000)

20,848

Average daily volume (3 m)

152,839

12m performance

0,40

0,30

0,20

0,10

0,00

16/11/19

16/01/20

16/03/20

16/05/20

16/07/20

16/09/20

16/09/19

ALSGD

ALSGD rel to CAC Small & Mid 190

Change (%)

1 m

3 m

12m

Absolute

-13.6

-21.5

-35.1

Rel. to CAC SM190

-14.2

-26.2

-27.0

Rel. to Next Biotech

-0.2

-4.0

-39.5

Financials (31/12)

EURm

2019

2020E

2021E

2022E

Sales

6.8

5.4

7.9

10.0

EBITDA

-0.1

-0.8

0.5

1.1

EBIT

-0.4

-1.0

0.2

0.8

Net income

-0.7

-1.7

-0.1

0.6

EPS (EUR)

0.0

-0.1

0.0

0.0

Net debt

4.7

4.9

3.1

4.4

Key ratios

2019

2020E

2021E

2022E

EV/Sales

1.1x

1.6x

0.8x

0.8x

EV/EBITDA

na

na

12.4x

7.1x

EV/EBIT

na

na

26.9x

9.7x

PER

na

na

na

6.0x

ROIC

-9%

na

5%

17%

ROE

12%

30%

2%

-6%

EV/IC

1.5x

1.7x

1.4x

1.6x

Gearing

-84%

-85%

-49%

-43%

The issuer and Biostrategic Partners have agreed that Biostrategic Partners will produce and disseminate investment research as a service

1

Alongside the historical ranges, DSG Connect (pad connected to the drilling device and having obtained the CE mark last April) is experiencing a slower launch than anticipated before the health crisis. Access to operating theaters is in fact restricted to healthcare personnel only, making it impossible to accompany surgeons by SpineGuard' teams. While the initial feedback from surgeons is very positive, the dissemination of information and the sharing of experience between physicians are less, especially since certain orthopedic surgery conferences have been canceled or are taking place in "virtual" mode, an organization not very conducive to discussions and other exchanges between suppliers of medical equipment and doctors (this affects all players in the MedTech sector).

Financial visibility

As of June 30, the cash position stands at EUR1.12m. The company has secured a new financing line of EUR2.4m which gives visibility until mid-2022. Without worsening global health situation, we believe the group should return to its objective of operational break even by the end of 2021.

Valuation and rating

When H1 sales were published last July, management mentioned the implementation of rigorous cost management during the lockdown period. The figures released last night are therefore no big surprise. However, the period remains complex for the sector and the activity of many MedTech players depends on that of hospitals. While the situation seems fairly stable in Europe, visibility in the US is not optimal and the resurgence of the virus in some states is likely to impact surgeries schedules. However, suffering patients must be operated on and it will be difficult to continually postpone operations. We therefore remain on our conservative scenario for 2020E with annual sales estimated at EUR5.4m (-21%).

Value creation is obviously dependent on sales of the PediGuard range, but DSG technology can and must become a "must have" in assisted surgery (robots). Developments in this area are progressing very satisfactorily and the collaboration with the Sorbonne is proceeding optimally (version 2 tests in progress). Sooner or later, this intellectual property will be valued with leading MedTech players. The company is making progress in this direction in making contacts with potential partners. Discussions are underway, with support from investment bank Healthios Capital.

The stock trades on levels that are definitively disconnected from the intrinsic value of the assets. A quick sector comparison reveals an abnormal discount that the current situation cannot explain. The safeguard procedure should in fact make it possible to renegotiate the debt repayment schedule. Business continuity is not in any way questioned.

We therefore remain positive on the dossier. We have adjusted our price target to take into account the successive dilutions resulting from the drawdowns of OCAPI tranches. It now stands at EUR0.85, representing a potential appreciation of + 394%.

Next communication:Q3 sales - 15th October 2020

2

Profit and Loss

As of 31/12 (EURm)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Sales

6.35

7.46

8.17

7.58

6.83

5.37

7.95

10.00

Change n-1

43.1%

17.6%

9.5%

-7.3%

-9.9%

-21.4%

48.0%

25.8%

Other revenues

-

-

-

-

-

-

-

-

Total revenues

6.35

7.46

8.17

7.58

6.83

5.37

7.95

10.00

Gross margin

5.36

6.35

6.95

6.55

5.77

4.59

7.01

8.89

EBITDA

-3.73

-3.31

-2.66

-0.86

-0.14

-0.76

0.54

1.13

Change n-1

12%

11%

20%

68%

84%

-460%

171%

-108%

Depreciation & amortisation

0.26

0.33

0.31

0.26

0.30

0.29

0.29

0.30

Goodwill

-

-

-

-

-

-

-

-

EBIT

-3.97

-3.63

-2.96

-1.11

-0.43

-1.05

0.25

0.83

Change n-1

11%

9%

18%

63%

61%

-143%

124%

-232%

Net financial income

0.10

-0.54

-1.16

-1.21

-0.64

-0.69

-0.36

-0.23

Minorities

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

Net profit before tax

-3.88

-4.18

-4.13

-2.32

-1.07

-1.74

-0.11

0.60

Tax

-

-

-

-0.02

0.39

-

-

-

Net in come

-3.88

-4.18

-4.13

-2.33

-0.69

-1.74

-0.11

0.60

Change n-1

15%

-8%

1%

43%

71%

-154%

94%

646%

EPS

-0.77

-0.82

-0.72

-0.34

-0.05

-0.10

-0.01

0.03

EPS fully diluted

-0.77

-0.75

-0.68

-0.38

-0.05

-0.09

-0.01

0.03

Gross margin (% of sales)

84.5%

85.1%

85.1%

86.5%

84.5%

85.5%

88.1%

88.9%

EBITDA (% of sales)

na

na

na

na

na

na

7%

11%

EBIT (% of sales)

na

na

na

na

na

na

3%

8%

Net margin (% of sales)

na

na

na

na

na

na

na

6%

Cash Flow statement

Au 31/12 (MEUR)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Net income

-3.88

-4.18

-4.13

-2.33

-0.69

-1.74

-0.11

0.60

Depreciation and amortisation

0.26

0.33

0.31

0.26

0.30

0.29

0.29

0.30

Goodwill

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Change in WCR

0.53

-1.01

0.26

-0.08

0.27

-0.60

-0.37

-0.14

Others

0.50

0.83

1.05

1.49

0.71

1.01

0.67

0.54

Cash-flow from operations

-2.60

-4.03

-2.51

-0.67

0.60

-1.05

0.49

1.30

Capex

-0.20

-0.06

-0.05

-0.05

-0.08

-0.08

-0.08

-0.08

Free cash flow

-2.80

-4.09

-2.56

-0.72

0.52

-1.13

0.41

1.22

Acquisitions

-0.37

-0.09

-

-

-0.15

-

-

-

Divestments

-

0.01

-

-

-

-

-

-

Dividends

-

-

-

-

-

-

-

-

Capital increase

2.64

0.42

2.21

1.68

1.75

-

-

-

Financing (bank and others)

2.76

2.87

0.01

4.64

0.22

-

-

-

Others

-1.51

-0.54

-0.26

-5.73

-1.54

-

-2.36

-2.53

Change in cash over the period

0.72

-1.42

-0.61

-0.13

0.80

-1.13

-1.96

-1.31

Opening cash position

2.51

3.23

1.80

1.19

1.05

2.01

0.88

-1.08

Closing cash position

3.23

1.80

1.19

1.06

1.85

0.88

-1.08

-2.39

3

Balance sheet

Au 31/12 (MEUR)

2015

2016

2017

2018

2019

2020E

2021E

2022E

Fixed assets

0.21

0.18

0.14

0.12

0.63

0.56

0.48

0.40

Intangible assets

1.26

1.11

0.90

0.72

0.72

0.59

0.45

0.31

Goodwill

3.08

3.08

3.08

3.08

3.08

3.08

3.08

3.08

Financial assets

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Inventories

0.59

1.02

0.81

0.84

0.66

0.53

0.79

0.99

Account receivables

0.94

1.41

1.38

1.32

0.95

0.90

1.34

1.68

Other receivables

0.54

0.68

0.54

0.59

0.55

0.50

0.39

0.58

Cash and cash equivalents

3.23

1.80

1.19

1.06

1.40

0.27

-1.68

-2.99

Prepaid expenses

-

-

-

-

-

-

-

-

Other non-current assets

0.06

0.13

0.12

0.13

0.12

0.12

0.12

0.12

Total assets

9.92

9.41

8.15

7.86

8.12

6.56

4.97

4.17

Equity

4.74

1.19

-0.20

-5.35

-5.57

-5.76

-6.36

-10.15

Others

-

-

-

4.86

5.78

5.78

8.15

10.68

Provisions

0.05

0.07

0.04

0.04

0.05

0.05

0.05

0.05

Financial debt

2.99

6.00

6.23

6.07

6.08

5.16

1.41

1.41

Account payables

1.10

1.19

1.04

1.16

1.04

0.68

1.01

1.27

Other debts

1.04

0.96

0.98

0.81

0.62

0.52

0.60

0.80

Deferred income and other liabilities

-

-

0.06

0.26

0.11

0.11

0.11

0.11

Total liabilities

9.92

9.41

8.15

7.86

8.12

6.56

4.97

4.17

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

SpineGuard SA published this content on 16 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2020 12:44:03 UTC


share with twitter share with LinkedIn share with facebook
All news about SPINEGUARD
10/20SPINEGUARD : strengthens its intellectual property with a new patent granted in ..
PU
10/20SPINEGUARD : Strengthens Its Intellectual Property With a New Patent Granted in ..
BU
10/1616 OCTOBER 2020 – 10H45 CET : SpineGuard morning note by BioStrategic Rese..
PU
10/15SPINEGUARD : reports third-quarter 2020 revenue
PU
10/15SPINEGUARD : Reports Third-quarter 2020 Revenue
BU
10/15SPINEGUARD : 3rd quarter earnings
CO
09/1616 SEPTEMBER 2020 – 10H45 CET : SpineGuard morning note by BioStrategic Re..
PU
09/15SPINEGUARD : Reports Six-Month 2020 Financial Results
PU
09/15SPINEGUARD : Reports Six-Month 2020 Financial Results
BU
09/15SPINEGUARD : Half-year results
CO
More news
Financials
Sales 2019 6,83 M 8,02 M 8,02 M
Net income 2019 -0,69 M -0,81 M -0,81 M
Net Debt 2019 4,80 M 5,64 M 5,64 M
P/E ratio 2019 -3,28x
Yield 2019 -
Capitalization 3,18 M 3,76 M 3,74 M
EV / Sales 2018 1,38x
EV / Sales 2019 0,99x
Nbr of Employees 14
Free-Float 99,5%
Chart SPINEGUARD
Duration : Period :
SpineGuard Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPINEGUARD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers
NameTitle
Pierre Jérôme Chairman & Chief Executive Officer
Manuel Lanfossi Chief Financial & Administrative Officer
Thibault Chandanson Director-Research & Development
Stéphane Bette Director & Deputy Chief Executive Officer
Maurice Bourlion Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SPINEGUARD-26.45%4
MASIMO CORPORATION51.94%13 802
NOVOCURE LIMITED36.86%12 080
ASAHI INTECC CO., LTD.-1.56%7 861
GETINGE AB3.19%5 626
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.54.87%4 705